Istvan A. Hajdu

ISTVAN HAJDU represents issuers, underwriters, selling stockholders and other parties in a variety of SEC-registered and exempt transactions, including initial public offerings, common and preferred equity offerings, rights offerings and debt offerings. He advises clients on corporate governance matters and ongoing disclosure obligations. His experience also includes advising on private equity, venture capital and M&A transactions.

Istvan is fluent in English and Hungarian and speaks Russian.

Representative transactions and experience include:

• Advising IO Biotech, Pyxis Oncology, Aprea Therapeutics, Tricida, CytomX Therapeutics and The New Home Company in connection with their IPOs
• Advising the underwriters in connection with the IPOs of SelectQuote, Great Western Bancorp, National Bank Holdings Corp., and Walker & Dunlop
• Advising the underwriters in connection with the IPOs of WhiteHorse Finance and Garrison Capital, as well as follow-on offerings by THL Credit, each a closed-end management company regulated under the Investment Company Act as a business development company
• Advising Tempest Therapeutics in connection with its merger with Millendo Therapeutics
• Advising Discover Financial Services in connection with debt offerings, ongoing disclosure obligations, and corporate governance matters
• Advising Alamo Group Inc. in connection with its ongoing disclosure obligations, corporate governance matters, and the SEC-registered sale of common stock by a large stockholder
• Advising the underwriters in connection with securities offerings by Chubb Ltd, American Financial Group, Inc., Carnival Corp., Carnival plc, Old Republic International Corporation, Westpac Banking Corporation, W. R. Berkley Corporation, and various other issuers
• Advising stockholders in connection with secondary transactions, including eBay Inc. in the sale of its holdings in MercadoLibre, Inc. 
• Advising issuers and dealers in connection with rights offerings and ATMs
• Advising issuers, investors, and placement agents in connection with Section 4(a)(2) and Regulation D private placements